BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
- PMID: 33979486
- PMCID: PMC8133696
- DOI: 10.1056/NEJMc2106083
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
Figures
Similar articles
-
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.N Engl J Med. 2021 Oct 21;385(17):1627-1629. doi: 10.1056/NEJMc2113468. Epub 2021 Sep 15. N Engl J Med. 2021. PMID: 34525276 Free PMC article. Clinical Trial. No abstract available.
-
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.N Engl J Med. 2021 Jun 24;384(25):2453-2454. doi: 10.1056/NEJMc2104036. Epub 2021 Apr 7. N Engl J Med. 2021. PMID: 33826815 Free PMC article. No abstract available.
-
Neutralizing Activity of BNT162b2-Elicited Serum.N Engl J Med. 2021 Apr 15;384(15):1466-1468. doi: 10.1056/NEJMc2102017. Epub 2021 Mar 8. N Engl J Med. 2021. PMID: 33684280 Free PMC article. No abstract available.
-
Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.Front Immunol. 2021 Mar 12;12:657711. doi: 10.3389/fimmu.2021.657711. eCollection 2021. Front Immunol. 2021. PMID: 33777055 Free PMC article. Review.
-
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines.Signal Transduct Target Ther. 2021 Jun 9;6(1):226. doi: 10.1038/s41392-021-00644-x. Signal Transduct Target Ther. 2021. PMID: 34108440 Free PMC article. Review. No abstract available.
Cited by
-
Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions.Emerg Microbes Infect. 2024 Dec;13(1):2412643. doi: 10.1080/22221751.2024.2412643. Epub 2024 Nov 13. Emerg Microbes Infect. 2024. PMID: 39392057 Free PMC article.
-
Development and evaluation of vaccination strategies for addressing the continuous evolution SARS-CoV-2 based on recombinant trimeric protein technology: Potential for cross-neutralizing activity and broad coronavirus response.Heliyon. 2024 Jul 17;10(14):e34492. doi: 10.1016/j.heliyon.2024.e34492. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39148990 Free PMC article.
-
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review.Vaccines (Basel). 2024 May 18;12(5):554. doi: 10.3390/vaccines12050554. Vaccines (Basel). 2024. PMID: 38793805 Free PMC article. Review.
-
Homologous and Heterologous Covid-19 Booster Vaccinations Against SARS-CoV-2 Infection in the Elderly.Curr Microbiol. 2024 May 13;81(7):171. doi: 10.1007/s00284-024-03689-7. Curr Microbiol. 2024. PMID: 38739274
-
Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial.Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118. Vaccines (Basel). 2024. PMID: 38400102 Free PMC article.
References
-
- Tchesnokova V, Kulakesara H, Larson L, et al. Acquisition of the L452R mutation in the ACE2-binding interface of spike protein triggers recent massive expansion of SARS-CoV-2 variants. March 11, 2021. (https://www.biorxiv.org/content/10.1101/2021.02.22.432189v2). preprint. - PMC - PubMed
-
- Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020. (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint.
-
- Tauzin A, Nayrac M, Benlarbi M, et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. March 18, 2021. (https://www.biorxiv.org/content/10.1101/2021.03.18.435972v1). preprint.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous